Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

120.36 +1.05 (+0.88%)
Streaming Delayed Price Updated: 2:39 PM EST, Feb 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,402,675
Open 119.01
Bid (Size) 120.34 (200)
Ask (Size) 120.39 (100)
Prev. Close 119.31
Today's Range 118.12 - 121.61
52wk Range 73.31 - 122.66
Shares Outstanding 2,531,374,696
Dividend Yield 2.82%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Zoetis Inc. (ZTS): Navigating Innovation and Safety in a Mature Animal Health Market
Zoetis Inc. (NYSE: ZTS) stands today as the undisputed global leader in animal health, a position it has fortified since its historic decoupling from Pfizer over a decade ago. As of February 12, 2026,... 
Via Finterra
Topics Artificial Intelligence Earnings Economy
News headline image
The Bioelectronic Frontier: A Deep-Dive into NovoCure’s Multi-Indication Transformation
The following research article examines NovoCure Limited (NASDAQ: NVCR) through a deep-dive lens, focusing on its pioneering role in bioelectronic oncology and its current strategic pivot as of... 
Via Finterra
Topics Initial Public Offering Intellectual Property

Performance

YTD
+13.1%
+13.1%
1 Month
+10.2%
+10.2%
3 Month
+31.6%
+31.6%
6 Month
+45.5%
+45.5%
1 Year
+39.1%
+39.1%

More News

Read More
News headline image
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
From Merck & Co., Inc.
Via Business Wire
Merck & Co. Inc. (NYSE:MRK) Beats Q4 Estimates but 2026 Outlook Cautions Investors ↗
Via Chartmill
News headline image
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
From Merck & Co., Inc.
Via Business Wire
News headline image
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
News headline image
Gilead’s Second Act: A 2026 Deep Dive into the Transition from Virology to Oncology Powerhouse
Via Finterra
Topics Economy Intellectual Property
News headline image
5 Revealing Analyst Questions From Merck’s Q4 Earnings Call
Via StockStory
Topics Earnings Intellectual Property
News headline image
Stock Market Today, Feb. 9: Oracle Climbs on AI Optimism Despite Software Sector Weakness ↗
Via The Motley Fool
Topics Artificial Intelligence Economy Stocks
News headline image
3 Top Dow Jones Dividend Stocks to Buy for Passive Income in 2026 ↗
Via The Motley Fool
Topics Economy Intellectual Property Stocks
News headline image
AstraZeneca’s Strategic Takeover of Modella AI Signals the Rise of Agentic Oncology
Via TokenRing AI
Topics Artificial Intelligence
News headline image
Fiscal Brinkmanship: Data Blackout and the DHS Cliff Loom Over Markets After Narrow Funding Deal
Via MarketMinute
Topics Economy Government Immigration
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Phoenix of Big Pharma: A 2026 Deep-Dive into AstraZeneca’s Global Dominance
Via Finterra
Topics Economy Government Intellectual Property
News headline image
Trump Administration To Launch TrumpRx Platform For Discounted Drugs Later On Thursday: Reports ↗
Via Stocktwits
Topics Economy Government World Trade
News headline image
USDA Unveils $100 Million 'Grand Challenge' to Thwart Flesh-Eating Screwworm as Threat Reaches U.S. Border
Via MarketMinute
Topics Death Economy
AI Panic Hits Software, PayPal Faceplants, Walmart Joins the $1T Club ↗
Via Chartmill
Topics Artificial Intelligence
News headline image
How Merck Is Preparing For The Patent Cliff Of Its Blockbuster Cancer Drug Keytruda ↗
Via Stocktwits
Topics Earnings Intellectual Property
News headline image
MRK Q4 Deep Dive: Pipeline Expansion and New Product Launches Shape Guidance
Via StockStory
News headline image
Merck (MRK) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Merck’s (NYSE:MRK) Q4 CY2025 Sales Beat Estimates
Via StockStory
Topics Earnings
News headline image
Merck & Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results; Highlights Progress Advancing Broad, Diverse Pipeline
From Merck & Co., Inc.
Via Business Wire
News headline image
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
Via MarketMinute
Topics Economy Government Intellectual Property
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
Merck (MRK) Q4 Earnings Report Preview: What To Look For
Via StockStory
Topics Artificial Intelligence

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 120.36
When was Merck & Co last traded?
The last trade of Merck & Co was at 02/12/26 02:39 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 304.68B
How many shares of Merck & Co are outstanding?
Merck & Co has 305B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.